The pain can range from cervical intervertebral discs, facet joints to atlantoaxial joints. Cervical discogenic pain syndrome is a common source of neck pain with a reported prevalence between 16% ...

including cervical and lumbar pain due to sacroiliac (SI) dysfunction, and finally discogenic pain. There are currently five randomized trials on the efficacy of RF facet denervation for low back ...

Also in February 2025, the FDA cleared the Company’s Investigational New Drug (IND) application for BRTX-100 for the treatment of chronic cervical discogenic pain (cCDP), expanding ...

The FDA IND clearance for evaluating BRTX-100 in treating chronic cervical discogenic pain suggests regulatory progress and potential for expanding treatment options, which can positively impact ...

We have also obtained FDA IND clearance to evaluate BRTX-100 in the treatment of chronic cervical discogenic pain. • Metabolic Program (ThermoStem ®): We are developing cell-based therapy ...

Detailed price information for Biorestorative Therapies Inc (BRTX-Q) from The Globe and Mail including charting and trades.

The second milestone achieved since the start of 2025 was the FDA clearing our investigational drug application for a Phase II clinical trial for BRTX-100 in chronic cervical discogenic pain or cCDP.

The use of facet median nerve branch radiofrequency ablation (RFA) for cervical, thoracic and lumbar ... are being introduced to treat discogenic pain. Sympathetic ganglion RFA is used to treat ...

With age or injury, the NP degenerates, leading to chronic “discogenic” back pain. VIVEX Biologics, a US-based biotechnology company that is focused on regenerative medicine, recently ...

Over time, the effects build up, and what once seemed like nothing can turn into a consistent and nagging pain. Unfortunately, some people are just genetically more prone to cervical problems.

Numeric Rating Scale (NRS) scores, a self-reported measure of pain intensity ranging from 0 (no pain) to 10 (worst possible pain), decreased from 7.1 at baseline to 3.8 at 12 months; 64% of ...